Every valuation, profitability, balance-sheet and per-share figure DeltaScreener holds for TaiGen Biopharmaceuticals Holdings Limited (4157.TWO), each with what it measures. Figures are trailing twelve months or the most recent reported period.
Valuation
Metric
Value
P/E ratioShare price divided by earnings per share.
42.57
P/B ratioShare price divided by book value per share.
6.23
P/S ratioMarket value divided by annual revenue.
24.81
EV / EBITDAEnterprise value against earnings before interest, tax, depreciation and amortisation.
63.94
EV / RevenueEnterprise value against annual revenue.
21.29
Earnings yieldEarnings per share as a percentage of the share price — the inverse of P/E.
2.35%
Profitability
Metric
Value
Gross marginRevenue left after the direct cost of goods sold.
93.69%
Operating marginRevenue left after operating costs.
-353.49%
Net marginRevenue left after every cost, including tax and interest.
60.49%
Return on equityProfit as a percentage of shareholders’ equity.
15.55%
Return on assetsProfit as a percentage of total assets.
4.81%
Financial health
Metric
Value
Current ratioCurrent assets divided by current liabilities. Above 1 means short-term assets cover short-term bills.
31.84
Quick ratioThe same, excluding inventory.
29.52
Debt to equityTotal borrowings against shareholders’ equity.
0.01
Per share and size
Metric
Value
Earnings per shareProfit attributable to each share.
$0.21
Book value per shareShareholders’ equity divided by shares outstanding.
$1.44
Shares outstandingShares currently issued.
711,834,000
Market capitalisationShare price times shares outstanding.
$6.36B
Enterprise valueMarket value plus net debt — what it would cost to buy the business outright.
$0
Dividend
Metric
Value
Dividend yieldAnnual dividend as a percentage of the share price.
0.00%
Payout ratioShare of profit paid out as dividends.
What is TaiGen Biopharmaceuticals Holdings Limited's P/E ratio?
TaiGen Biopharmaceuticals Holdings Limited (4157.TWO) trades on a price-to-earnings ratio of 42.57.
What is TaiGen Biopharmaceuticals Holdings Limited's return on equity?
TaiGen Biopharmaceuticals Holdings Limited (4157.TWO) reports a return on equity of 15.55%, meaning it generated that much profit for every dollar of shareholders' equity.
How much debt does TaiGen Biopharmaceuticals Holdings Limited carry?
TaiGen Biopharmaceuticals Holdings Limited (4157.TWO) has a debt-to-equity ratio of 0.01, which compares total borrowings with shareholders' equity.
What is TaiGen Biopharmaceuticals Holdings Limited's profit margin?
TaiGen Biopharmaceuticals Holdings Limited (4157.TWO) keeps 60.49% of revenue as net profit after every cost, including tax and interest.